The Role of Interferon in Hepatitis B TherapyReportar como inadecuado

The Role of Interferon in Hepatitis B Therapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Current Hepatitis Reports

, Volume 9, Issue 4, pp 231–238

First Online: 26 August 2010


Despite the introduction of new nucleostide analogues in recent years, peginterferon is still recommended as a potential first-line treatment option by current practice guidelines for the management of chronic hepatitis B. Peginterferon offers the advantage of higher sustained off-treatment response rates compared to nucleostide analogues because of its immunomodulatory effects. Sustained transition to the inactive hepatitis B surface antigen HBsAg carrier state can be achieved in about 30% of hepatitis B e antigen HBeAg–positive patients and 20% of HBeAg-negative patients. Recent studies have focused on identification of pretreatment and on-treatment factors that allow the selection of patients who are likely to achieve a sustained response to peginterferon therapy in order to avoid the side-effects and costs associated with unnecessary treatment. Future studies need to address whether specific virologic benchmarks can guide individualized decisions concerning therapy continuation and whether peginterferon combined with new potent nucleostide analogues improves treatment outcomes.

KeywordsHBV Antiviral therapy Interferon Nucleostide analogues  Download fulltext PDF

Autor: Vincent Rijckborst - Harry L. A. Janssen


Documentos relacionados